Michael J Mckenna

US Patent:

7723050, May 25, 2010

Filed:

Jul 10, 2009

Appl. No.:

12/501385

Inventors:

Michael S. Urdea - Alamo CA, US
Michael P. McKenna - Oakland CA, US
Patrick A. Arensdorf - Palo Alto CA, US

Assignee:

Tethys Bioscience, Inc. - Emeryville CA

International Classification:

G01N 33/53

US Classification:

435 71, 435 2, 435 721, 436501, 436518, 436522, 422 50, 422 61

Abstract:

The invention describes biomarkers which can be used to predict the likelihood that an individual will develop Diabetes. The biomarkers can also be used to screen large groups in order to identify individuals at risk of developing Diabetes.

US Patent:

8097425, Jan 17, 2012

Filed:

Mar 12, 2007

Appl. No.:

11/717280

Inventors:

Michael S. Urdea - Alamo CA, US
Michael P. McKenna - Berkeley CA, US
Scott Eastman - Danville CA, US

Assignee:

Tethys Bioscience, Inc. - Emeryville CA

International Classification:

G01N 33/53
G01N 31/00

US Classification:

435 721, 435 2, 435 71, 436501, 436518, 436522, 530300, 530350, 422 50

Abstract:

The invention provides methods, compositions, and kits for multiplex fractionation of proteins in a sample. Protein-binding molecules, such as small epitope antibodies or small epitope aptamers, are used for multiplex fractionation of proteins in a protein containing sample. Detection of fractionated proteins may be used for characterization of proteins in a sample in applications such as expression profiling, identification and/or quantification of proteins in a sample, and identification or detection of biomarkers.

US Patent:

8119358, Feb 21, 2012

Filed:

Apr 18, 2008

Appl. No.:

12/106070

Inventors:

Michael S. Urdea - Alamo CA, US
Michael P. McKenna - Oakland CA, US
Patrick A. Arensdorf - Palo Alto CA, US

Assignee:

Tethys Bioscience, Inc. - Emeryville CA

International Classification:

G01N 33/53

US Classification:

435 721, 435 71, 436 1, 436501, 436518, 424 91, 424520, 422 1, 422 50, 422 60, 530300, 530350

Abstract:

The invention describes biomarkers which can be used to predict the likelihood that an individual will develop Diabetes. The biomarkers can also be used to screen large groups in order to identify individuals at risk of developing Diabetes.

US Patent:

8232065, Jul 31, 2012

Filed:

May 8, 2007

Appl. No.:

12/300019

Inventors:

Michael S. Urdea - Alamo CA, US
Michael P. McKenna - Oakland CA, US

Assignee:

Tethys Bioscience, Inc. - Emeryville CA

International Classification:

G01N 31/00
G01N 33/53

US Classification:

435 721, 435 71, 436501, 436518, 424 91, 424520, 422 50, 530300, 530350

Abstract:

Disclosed are systems and methods for developing diagnostic tests (e. g. , detection, screening, monitoring, and prognostic tests) based on biomarker information from legacy clinical sample sets, for which only small sample volumes (e. g. , about 0. 05 to about 1. 0 mL or less per sample) are typically available. For example, biomarkers (e. g. , about 10, 50, 100, 150, 200, 300, or more) may be detected in the clinical samples through the use of single molecule detection and each biomarker may be detected in an assay that includes about 1 μL or less of a legacy clinical sample.

US Patent:

8357497, Jan 22, 2013

Filed:

Jul 30, 2012

Appl. No.:

13/561913

Inventors:

Michael S. Urdea - Alamo CA, US
Michael P. McKenna - Branford CT, US

Assignee:

Tethys Bioscience, Inc. - Emeryville CA

International Classification:

G01N 33/53
G01N 31/00

US Classification:

435 71, 435 721, 436501, 424 91, 424520, 422 50, 530300, 530350

Abstract:

Disclosed are systems and methods for developing diagnostic tests (e. g. , detection, screening, monitoring, and prognostic tests) based on biomarker information from legacy clinical sample sets, for which only small sample volumes (e. g. , about 0. 05 to about 1. 0 mL or less per sample) are typically available. For example, biomarkers (e. g. , about 10, 50, 100, 150, 200, 300, or more) may be detected in the clinical samples through the use of single molecule detection and each biomarker may be detected in an assay that includes about 1 μL or less of a legacy clinical sample.

US Patent:

8409816, Apr 2, 2013

Filed:

Oct 5, 2011

Appl. No.:

13/253578

Inventors:

Michael S. Urdea - Alamo CA, US
Michael P. McKenna - Oakland CA, US
Patrick A. Arensdorf - Palo Alto CA, US

Assignee:

Tethys Bioscience, Inc. - Emeryville CA

International Classification:

G01N 31/00
G01N 33/53

US Classification:

435 721, 435 71, 436501, 436518, 424 91, 424520, 530300, 530350

Abstract:

The invention describes biomarkers which can be used to predict the likelihood that an individual will develop Diabetes. The biomarkers can also be used to screen large groups in order to identify individuals at risk of developing Diabetes.

US Patent:

20070218519, Sep 20, 2007

Filed:

Oct 11, 2006

Appl. No.:

11/546874

Inventors:

Mickey Urdea - Alamo CA, US
Michael McKenna - Berkeley CA, US
Patrick Arensdorf - Palo Alto CA, US

Assignee:

Tethys Bioscience, Inc. - Emeryville CA

International Classification:

G01N 33/00

US Classification:

435007920

Abstract:

Disclosed are methods of identifying subjects with Diabetes or a pre-diabetic condition, methods of identifying subjects at risk for developing Diabetes or a pre-diabetic condition, methods of differentially diagnosing diseases associated with Diabetes or a pre-diabetic condition from other diseases or within sub-classifications of Diabetes, methods of evaluating the risk of progression to Diabetes or a pre-diabetic condition in patients, methods of evaluating the effectiveness of treatments in subjects with Diabetes or a pre-diabetic condition, and methods of selecting therapies for treating Diabetes or a pre-diabetic condition, using biomarkers.

US Patent:

20070259377, Nov 8, 2007

Filed:

Apr 18, 2007

Appl. No.:

11/788260

Inventors:

Mickey Urdea - Alamo CA, US
Michael McKenna - Berkeley CA, US
Patrick Arensdorf - Palo Alto CA, US

International Classification:

G01N 33/53

US Classification:

435007100

Abstract:

Disclosed are methods of identifying subjects with Diabetes, pre-Diabetes, or a pre-diabetic condition, methods of identifying subjects at risk for developing Diabetes, pre-Diabetes, or a pre-diabetic condition, methods of differentially diagnosing diseases associated with Diabetes, pre-Diabetes, or a pre-diabetic condition from other diseases or within sub-classifications of Diabetes, methods of evaluating the risk of progression to Diabetes, pre-Diabetes, or a pre-diabetic condition in patients, methods of evaluating the effectiveness of treatments in subjects with Diabetes, pre-Diabetes, or a pre-diabetic condition, and methods of selecting therapies for treating Diabetes, pre-Diabetes or a pre-diabetic condition, using biomarkers.